[HTML][HTML] Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients
D Fujimoto, K Uehara, Y Sato, I Sakanoue, M Ito… - Scientific reports, 2017 - nature.com
Concurrent chemoradiation therapy (CCRT) is the treatment of choice for locally advanced
non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell …
non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell …
Natural history and clinical characteristics of multiple pulmonary nodules with ground glass opacity
…, T Morimoto, K Uehara, K Nagata, I Sakanoue… - …, 2017 - Wiley Online Library
Background and objective Ground glass nodules ( GGNs ) are frequently encountered in
the lungs. We report the natural history and characteristics of multiple GGNs , and propose a …
the lungs. We report the natural history and characteristics of multiple GGNs , and propose a …
[HTML][HTML] Expert consensus on perioperative treatment for non-small cell lung cancer
…, DH Owen, M Rodriguez, I Sakanoue… - Translational Lung …, 2022 - ncbi.nlm.nih.gov
… Ichiro Sakanoue: Because of our current status stated above, I do not have a definitive
answer for this question. However, based on the results from the ADAURA trial, I would prefer …
answer for this question. However, based on the results from the ADAURA trial, I would prefer …
[HTML][HTML] Efficacy and safety of thoracoscopic pericardial window in patients with pericardial effusions: a single-center case series
I Sakanoue, H Hamakawa, Y Okubo, K Minami… - Journal of cardiothoracic …, 2016 - Springer
Background Pericardial effusion (PE) is a common finding in patients who had chronic
cardiac failure, who had undergone cardiac surgery, or who had certain other benign and …
cardiac failure, who had undergone cardiac surgery, or who had certain other benign and …
Comparison of PD-L1 assays in non-small cell lung cancer: 22C3 pharmDx and SP263
…, R Tachikawa, N Date, I Sakanoue… - Anticancer …, 2018 - ar.iiarjournals.org
Background/Aim: While the PD-L1 22C3 pharmDx assay is an FDA-approved diagnostic
assay for pembrolizumab use, not every pathology laboratory has the Dako Autostainer to use …
assay for pembrolizumab use, not every pathology laboratory has the Dako Autostainer to use …
A CLUE for better assessment of donor lungs: novel technique in clinical ex vivo lung perfusion
BACKGROUND The direCt Lung Ultrasound Evaluation (CLUE) technique was proven to be
an accurate method for monitoring extravascular lung water in donor lungs during ex vivo …
an accurate method for monitoring extravascular lung water in donor lungs during ex vivo …
[HTML][HTML] Real-time lung weight measurement during cellular ex vivo lung perfusion: An early predictor of transplant suitability
Background. Increased extravascular lung water during ex vivo lung perfusion (EVLP) is
associated with ischemia reperfusion injury and poor pulmonary function. A non-invasive …
associated with ischemia reperfusion injury and poor pulmonary function. A non-invasive …
Reduced tumour proportion scores for programmed cell death ligand 1 in stored paraffin tissue sections
…, A Nakagawa, K Otsuka, I Sakanoue… - Anticancer …, 2018 - ar.iiarjournals.org
Background/Aim: We evaluated the effects of storage of formalin-fixed, paraffin-embedded (FFPE)
sections on the tumour proportion score (TPS) for programmed cell death ligand 1 (PD-…
sections on the tumour proportion score (TPS) for programmed cell death ligand 1 (PD-…
Prone ex vivo lung perfusion protects human lungs from reperfusion injury
…, T Okamoto, KS Ayyat, Y Itoda, I Sakanoue… - Artificial …, 2022 - Wiley Online Library
Background We previously reported beneficial effects of prone positioning during ex vivo
lung perfusion (EVLP) using porcine lungs. In this study, we sought to determine if prone …
lung perfusion (EVLP) using porcine lungs. In this study, we sought to determine if prone …
[HTML][HTML] KRAS mutation-positive mucinous adenocarcinoma originating in the thymus
I Sakanoue, H Hamakawa, D Fujimoto… - Journal of Thoracic …, 2017 - ncbi.nlm.nih.gov
Thymic carcinoma is a rare, aggressive disease with a low 5-year survival rate. The most
common histological neoplastic thymic tumor subtype is squamous cell. We describe an …
common histological neoplastic thymic tumor subtype is squamous cell. We describe an …